📣From lead to pre-candidate nomination in 18 months. Explore the STORM Therapeutics case study

Contact
  • Integrated Drug Discovery

    Integrated Drug Discovery

    Overview

    We deliver truly integrated drug discovery programs. Our co-located teams accelerate compounds from target ID to candidate.

  • Target Identification & Validation

    Target Identification & Validation

    It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.

  • Hit Identification

    Hit Identification

    Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.

  • Hit-to-Lead

    Hit-to-Lead

    High-quality hits with early proof of concept are de-risked and profiled, ready to accelerate your program towards lead optimization.

  • Lead Optimization

    Lead Optimization

    Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.

Featured Resources

  • Modalities

    Modalities

    Overview

    Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.

  • Small Molecules

    Small Molecules

    Expert small molecule discovery from target ID to scale-up, delivering candidates designed for success and market impact.

  • Peptides

    Peptides

    Transforming complex peptide concepts into next-generation therapies through integrated design, advanced analytics, and collaborative end-to-end discovery expertise.

  • Targeted protein degradation

    Targeted protein degradation

    Leveraging induced proximity and CHARMED technology to rapidly design, test, and optimize degraders for previously ‘undruggable’ targets.

  • ADCs

    ADCs

    Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.

  • Biologics

    Biologics

    Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.

Featured Resources

  • Therapeutic Areas

    Therapeutic Areas

    Overview

    Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.

  • Oncology and Immuno-Oncology

    Oncology and Immuno-Oncology

    Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.

  • Inflammation and Immunology

    Inflammation and Immunology

    Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.

  • Neuroscience

    Neuroscience

    Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.

  • Metabolic Diseases

    Metabolic Diseases

    Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.

Featured Resources

  • CellCentric Lead Optimisation Campaign - CCS1477

    CellCentric Lead Optimisation Campaign - CCS1477

    Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.

    Case study
  • About Sygnature

    About Sygnature

    At Sygnature Discovery, we deliver world-leading drug discovery solutions to accelerate your compound from idea to clinic.

  • Meet our Team

    Meet our Team

    Our leadership team brings diverse experience and insight, driving collaboration and innovation across drug discovery.

  • Careers

    Careers

    Explore careers at Sygnature Discovery and join a global team committed to science, collaboration, and integrity.

Search Results

Search across news, resources and pages to quickly find relevant content on our site.

Loading…
News
Sygnature and Epigeneron, the Japanese Bio-Venture, Join Forces in Collaboration
Discovering New Frontiers: Sygnature and Epigeneron Join Forces for Innovative Drug Target Identification Sygnature Discovery…
News
Sygnature et Epigeneron, la société japonaise de biotechnologie, unissent leurs forces dans le cadre d’une collaboration.
Découvrir de nouvelles frontières : Sygnature et Epigeneron unissent leurs forces pour l’identification de cibles…
Blog
To hallucinate, or not to hallucinate – that is the question
The explosion of research interest, clinical development and funding of psychedelic therapeutics for disorders…
Blog
The metastatic cancer challenge
One in two of us will be affected by cancer in our lifetimes, with one…
Blog
Hitting the drug target takes teamwork
Drug discovery programmes can be made or broken by the approaches organisations take in…
Blog
Formulating for success: A game-changing new facility
This month sees the official opening of our new Form and Formulation department. But why…
Blog
Making the right choices in hit identification
Like all parts of the drug discovery phases, successful hit identification is as much…
Blog
Hit-to-lead: It takes integration
So your hit clusters have been identified and validated in the earlier development process. Now…
Blog
Lead Optimisation: A question of quality
The aim of the lead optimisation stage is to move potent and safe drug candidates…
Blog
Your hits just got real: The value of active-to-hit
In any drug discovery project, even the slightest misstep can waste significant budget and time.
Blog
Tips for success in candidate profiling – and beyond
Candidate profiling, or late lead optimisation, is the final stage of de-risking and optimising…
Blog
Investing in the next generation of scientists
For drug discovery to continue making breakthroughs in medicine and healthcare, we’ve got to keep…
News
New CFO Jordison steps up
Sygnature has appointed Louisa Jordison as Chief Financial Officer. We’re aiming to build on…
News
Le nouveau directeur financier, Jordison, prend ses fonctions.
Sygnature a nommé Louisa Jordison au poste de directrice financière. Nous ambitionnons de consolider…
Blog
Meet the Expert: Farhan Taherali
In the first of a new series where we get to know some of the…
Blog
Leadership Perspectives: Andy Black on company culture
Life sciences entrepreneur Andy is a business expert – and a big believer in getting…
News
Expansions, transactions and all action: Our 2021 recap!
2021 is nearly over – and what a year it’s been for Sygnature! From key…
Blog
Synthetic chemistry in focus at From Farm to Pharma
We were pleased to host the final ELRIG networking event of 2021 last month at…
News
Sygnature strengthens with MedChemica software solution
We’ve strengthened our drug discovery offering even further – by licensing industry-leading software for lead…
Blog
Alzheimer’s disease and neurodegeneration: A brighter outlook?
Alzheimer’s disease (AD) is a devastating disease for the patient, their family and…
News
Our new Chairman: Dr Charles Woler
We’ve appointed the highly experienced pharmaceutical executive Dr Charles Woler as Chairman.   In…
Load More

Support

Can't find what you're looking for?

Can't find what you're looking for? Our team can help — whether you need assistance locating a resource, have a research enquiry, or want media information, get in touch and we'll point you in the right direction.

Get in touch